NCT02836028撤回2 期
A Phase 2, Multiple-Cohort, Open-Label, International Study of Talazoparib Monotherapy and Talazoparib Plus Temozolomide in Women With Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- Pfizer
- 主要终点
- Determine Objective Response Rate (ORR)
研究概览
简要总结
The purpose of this phase 2, multiple-cohort, randomized, open-label, international study of talazoparib (a poly (ADP-ribose) polymerase (PARP) inhibitor) is to compare the efficacy and safety of talazoparib monotherapy and talazoparib plus temozolomide in women with relapsed ovarian, fallopian tube, and peritoneal cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women ≥ 18 years of age and willing and able to provide informed consent
- •Relapsed, histologically confirmed ovarian, fallopian tube, and peritoneal cancer. Histologic subtypes include serous, endometrioid, clear-cell, mixed, undifferentiated histology, and carcinosarcoma.
- •Sufficient archival tumor tissue available or consent to a fresh tissue biopsy for biomarker analysis. Consent to blood sample collection for biomarker analysis is required.
- •Disease progression per RECIST 1.1 during or after the last treatment. Have metastatic disease with at least 1 target tumor lesion measurable per RECIST 1.1 on the screening scan. Lesions used for biopsies cannot be designated as a measurable lesion for RECIST 1.1 assessments.
- •Additional criteria for cohort 1 include the following:
- •Have a deleterious germline or a somatic BRCA1 or BRCA2 mutation, or a high diagnostic HRD test score (myChoice score ≥ 42), which represents a loss of DNA repair function based on testing performed at a sponsor-approved laboratory
- •Received at least 1 and no more than 3 platinum-based chemotherapy regimens (prior bevacizumab is allowed) and the last dose is ≥ 28 days before randomization
- •No prior PARP inhibitor treatment (COHORT 1 ONLY)
- •Additional criteria for cohorts 2 and 3 include the following:
- •Received at least 2 platinum-based chemotherapy regimens (including first-line chemotherapy; prior bevacizumab is allowed) and the last dose is ≥ 28 days before randomization
- •Received prior PARP inhibitor treatment as a single agent or in combination therapy regimen and the last dose is ≥ 28 days before randomization, as follows:
- •For cohort 2 only: Received PARP inhibitor treatment for ≥ 6 months and had a response of CR, PR, or stable disease for ≥ 6 months
- •For cohort 3 only: Received PARP inhibitor treatment for < 6 months with no response (disease progression or stable disease)
- •Eastern Cooperative Oncology Group (ECOG) performance status of ≤
- •Estimated life expectancy of ≥ 3 months.
- •Able to swallow drugs, have no known intolerance to study drugs or excipients, and able to comply with study requirements.
排除标准
- •Have not recovered (recovery is defined as National Cancer Institute Common Terminology Criteria for Adverse Events [CTCAE] grade ≤ 1) from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.
- •Use of any investigational agent within 14 days before randomization.
- •Had > 2 paracentesis procedures within 28 days before randomization.
- •Major surgery within 14 days before randomization.
- •Requirement for intravenous alimentation (at the time of randomization).
- •Diagnosis of MDS.
研究组 & 干预措施
talazoparib
Experimental
Cohorts 1A (PARP inhibitor naïve), 2A (PARP inhibitor sensitive), and 3A (PARP inhibitor refractory)
干预措施: Talazoparib (Drug)
talazoparib + temozolomide
Active Comparator
Cohorts 1B (PARP inhibitor naïve), 2B (PARP inhibitor sensitive), and 3B (PARP inhibitor refractory)
干预措施: Talazoparib (Drug)
talazoparib + temozolomide
Active Comparator
Cohorts 1B (PARP inhibitor naïve), 2B (PARP inhibitor sensitive), and 3B (PARP inhibitor refractory)
干预措施: Temozolomide (Drug)
结局指标
主要结局
Determine Objective Response Rate (ORR)
时间窗: Anticipated in about 44 months following first patient enrolled
次要结局
- PFS at 24 weeks(Anticipated in about 44 months following first patient enrolled)
- Overall survival(Anticipated in about 44 months following first patient enrolled)
- Pharmacokinetics of talazoparib as assessed by trough plasma concentrations(Anticipated in about 44 months following first patient enrolled)
- Progression-free survival (PFS)(Anticipated in about 44 months following first patient enrolled)
- Gynecologic Cancer Intergroup (GCIG) CA125 response rate(Anticipated in about 44 months following first patient enrolled)
- Clinical benefit rate at 24 weeks(Anticipated in about 44 months following first patient enrolled)
- Time to response(Anticipated in about 44 months following first patient enrolled)
- Safety as assessed by percentage of patients with any Adverse Event (AE), AE leading to Study Drug Discontinuation, AE leading to death, SAE, AE related to study drug, SAE related to study drug.(Anticipated in about 44 months following first patient enrolled)
- Duration of response (DOR)(Anticipated in about 44 months following first patient enrolled)
研究者
相似试验
已完成
2 期
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate CancerProstate CancerNCT03148795Pfizer128
已完成
2 期
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT01087151Genentech, Inc.118
终止
2 期
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene MutationNCT02034916Pfizer84
终止
1 期
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin LymphomaNon Hodgkin LymphomaNCT06088654Innate Pharma23
已完成
2 期
Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast CancerMetastatic Breast CancerNCT02491983MedSIR486